Infliximab In an article appearing in the journal TheLancet in 2002, medical researchers reported on theexperimental use of the arthritis drug infliximab in treatingCrohn’s disease. In a trial, 573 patients were given initial5-mg injections of the drug. Two weeks later, 335 hadresponded positively. These patients were then randomlyassigned to three groups. Group I received continuedinjections of a placebo, Group II continued with 5 mg ofinfliximab, and Group III received 10 mg of the drug. After30 weeks, 23 of 110 Group I patients were in remission,compared with 44 of 113 Group II and 50 of 112 Group IIIpatients. Do these data indicate that continued treatmentwith infliximab is of value for Crohn’s disease patientswho exhibit a positive initial response to the drug?
Infliximab In an article appearing in the journal The
Lancet in 2002, medical researchers reported on the
experimental use of the arthritis drug infliximab in treating
Crohn’s disease. In a trial, 573 patients were given initial
5-mg injections of the drug. Two weeks later, 335 had
responded positively. These patients were then randomly
assigned to three groups. Group I received continued
injections of a placebo, Group II continued with 5 mg of
infliximab, and Group III received 10 mg of the drug. After
30 weeks, 23 of 110 Group I patients were in remission,
compared with 44 of 113 Group II and 50 of 112 Group III
patients. Do these data indicate that continued treatment
with infliximab is of value for Crohn’s disease patients
who exhibit a positive initial response to the drug?
Trending now
This is a popular solution!
Step by step
Solved in 3 steps with 2 images
